IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

NPC Clinical Trial

Official title:
The Phase Ib/II, Open-label, Multicenter Study of IBI310 (Anti-CTLA4 mAb) in Combination With Sintilimab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma That Failed Prior Anti-PD-1/PD-L1 Therapy

Status Completed

Clinical Trial Summary

This is a phase 1b/II, open label, multicenter study of IBI310 (Anti-CTLA4 mAb) in combination with Sintilimab in patients with recurrent/metastatic Nasopharyngeal Carcinoma that failed prior Anti-PD-1/PD-L1 therapy

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04945421
Study type	Interventional
Source	Innovent Biologics (Suzhou) Co. Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	July 23, 2021
Completion date	February 6, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03352778` - IMRT vs 2DRT for NPC Patients
Active, not recruiting	`NCT03734809` - NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer	Phase 2
Recruiting	`NCT03158324` - Phase IIa Dose-Expansion and Biomarker Study of OPB-111077	Phase 2
Recruiting	`NCT03919552` - Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma	Phase 3
Not yet recruiting	`NCT04284332` - Phase II Prospective Study of Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC)	Phase 2
Completed	`NCT03973723` - Plasma EBV DNA Monitoring in Post-treatment NPC Patients
Active, not recruiting	`NCT01744587` - Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients	N/A